[Clinical evaluation of @entity2892 /cilastatin sodium in XXXX ].

@entity1 @entity295 @entity2892 @entity55 @entity2348 @entity5389 @entity9234 @entity281 @entity3552 @entity2259
Nine pediatric @entity1 with moderate or severe @entity2348 (3 @entity295 or @entity2259 , 2 @entity3552 , @entity5389 , 1 @entity55 and 1 pyothorax) in hospital were treated with @entity2892 / @entity9234 . The drug was administered intravenously by 30 or 60 minutes drip infusion in 3 or 4 divided doses totalling 24 mg/24 mg-70.2 mg/70.2 mg per kg/day. Clinical effectiveness were excellent in 4 cases, good in 2 cases, poor in 2 cases and not evaluated in 1 case. The overall efficacy rate was 75%. A slight decrease of WBC was observed in 1 case. It was concluded that @entity2892 / @entity9234 was a useful antibiotic for the treatment of @entity281 in pediatric practices. Pharmacokinetics of intravenously administered @entity2892 / @entity9234 was studied in 2 other cases. The @entity2892 / @entity9234 was administered intravenously by 30 or 60 minutes drip infusion to 2 cases at a dose of 10 mg/10 mg/kg. The mean half-life (T1/2) of @entity2892 was 1.03 hours and @entity9234 , 0.69 hour. The mean urinary recovery rate of @entity2892 within 6.5-7 hours after administration was 62.5% and @entity9234 , 76.7%.
